GM Moves Vehicle Production to Michigan
General Motors (NYSE:GM) said Tuesday it will move production of a gas-powered SUV to an assembly plant in Michigan and add manufacturing of pickup trucks in its home state.“GM will begin production of the Cadillac Escalade, as well as the Chevrolet Silverado and GMC Sierra light duty pickups at Orion Assembly in early 2027 to help meet continued strong customer demand,” the Detroit automaker said in a statement. The Escalade is currently produced in Arlington, Texas. The Silverado and Sierra trucks are made at an assembly plant in Fort Wayne, Indiana, which will continue to produce the vehicles. GM said it is adding more production of the trucks to its Orion Assembly plant in Michigan because of strong demand.The move builds on GM’s plans to invest $4 billion in U.S. facilities, which the automaker announced in June. That announcement came after President Donald Trump earlier this year implemented 25% tariffs on imported vehicles and 25% duties on many auto parts imported into the U.S.It also builds on the automaker’s gas-powered vehicle production. CEO Mary Barra had said in 2021 that GM would exclusively offer EVs by 2035, but the automaker has since said customer demand for EVs has been slower than expected and has shifted plans to meet consumer demand.GM shares began Wednesday ahead 61 cents, or 1.2%, to $53.35.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


